Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 1, 2007, Pages 83-88

  Lekhanont, Kaevalin ^a   Park, Choul Yong ^a   Combs, Juan Castro ^a   Suwan Apichon, Olan ^b   Rangsin, Ram ^c   Chuck, Roy S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KHON KAEN UNIVERSITY   (Thailand)

^c PHRAMONGKUTKLAO HOSPITAL   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN B; EPINASTINE; EYE DROPS; FLUORESCEIN; LUBRICATING AGENT; OLOPATADINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; DRY EYE; EXPERIMENTAL MODEL; FEMALE; KERATOCONJUNCTIVITIS SICCA; LACRIMATION; MOUSE; NONHUMAN; SCORING SYSTEM; STAINING;

ADMINISTRATION, TOPICAL; ANIMALS; BOTULINUM TOXINS; DIBENZAZEPINES; DIBENZOXEPINS; DISEASE MODELS, ANIMAL; FEMALE; HISTAMINE H1 ANTAGONISTS; IMIDAZOLES; KERATOCONJUNCTIVITIS SICCA; MICE; MICE, INBRED CBA; TEARS;

EID: 33947374686     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.0097     Document Type: Article

References (19)

1. Crandall, D.C., and Leopold, I.H. The influence of systemic drugs on tear constituents. Ophthalmology 86:115-125, 1979.
2. Polak, B.C. Side-effects of drugs and tear secretion. Doc. Ophthalmol. 67:115-117, 1987.
3. Nielsen, N.V., and Eriksen, J.S. Timolol transitory manifestations of dry eyes in long-term treatment. Acta. Ophthalmol. (Copenh.) 57:418-424, 1979.
4. Levine, L. Clinical implications of reported timolol-induced side-effects. Am. J. Optom. Physiol. Opt. 59: 523-528, 1982.
5. Welch, D., Ousler, G.W. 3rd, Nally, L.A., et al. Ocular drying associated with oral antihisfamines (loratadine) in the normal population-an evaluation of exaggerated dose effect. Adv. Exp. Med. Biol. 506(Pt. B):1051-1055, 2002.
6. Jaanus, S.D. Ocular side-effects of selected systemic drugs. Optom. Clin. 2:73-96, 1992.
7. Lambert, R.W., Kelleher, R.S., Wickham, L.A., et al. Neural-endocrine control of secretory component synthesis by lacrimal gland acinar cells: Specificity, temporal characteristics, and molecular basis. Adv. Exp. Med. Biol. 350:175-180, 1994.
8. Handley, D.A., McCullough, J.R., Fang, Y., et al. Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine. Ann. Allergy Asthma Immunol. 78:164, 1997.
9. Cardelus, I., Puig, J., Bou, J., et al. Xerostomia and mydriasis, two muscarinic peripheral side-effects associated with descarboethoxyloratadine, the main metabolite of loratadine. Br. J. Pharmaco. 123(Suppl):267, 1998.
10. Cardelus, I., Anton, F., Beleta, J., et al. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur. J. Pharmacol. 374:249-254, 1999.
11. Koffler, B.H., and Lemp, M.A. The effect of an antihistamine (chlorpheniramine maleate) on tear production in humans. Ann. Ophthalmol. 12:217-220, 1980.
12. Ousler, G.W., Wilcox, K.A., Gupta, G., et al. An evaluation of the ocular drying effects of 2 systemic antihistamines: Loratadine and cetirizine hydrochloride. Ann. Allergy Asthma Immunol. 93:460-464, 2004.
13. Suwan-apichon, O., Rizen, M., Rangsin, R., et al. Botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. Invest. Ophthalmol. Vis. Sci. 47: 133-139, 2006.
14. Moss, S.E., Klein, R., and Klein, B.E. Incidence of dry eye in an older population. Arch. Ophthalmol. 122:369-373, 2004.
15. Bielory, L. Role of antihistamines in ocular allergy. Am. J. Med. 113(Suppl. 9A):34S-37S, 2002.
16. Howell, G., 3rd, West, L., Jenkins, C., et al. In vivo antimuscarinic actions of the third-generation antihistaminergic agent, desloratadine. BMC Pharmacol. 5:13-14, 2005.
17. Villareal, A.L., Farley, W., Pflugfelder, S.C. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 32:272-276, 2006.
18. Kreutner, W., Hey, J.A., Anthes, J., et al. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. First communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung 50:345-352, 2000.
19. Dogru, M., Ozmen, A., Erturk, H., et al. Changes in tear function and the ocular surface after topical olopatadine treatment for allergic conjunctivitis: An open-label study. Clin. Ther. 24:1309-1321, 2002.